PNC Financial Services Group’s KalVista Pharmaceuticals KALV Stock Holding History

PNC Financial Services Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3K	Buy	149 +3	+2%	+$48	﹤0.01%	4459
2025 Q4	$2.36K	Sell	146 -27	-16%	-$358	﹤0.01%	4489
2025 Q3	$2.11K	Sell	173 -351	-67%	-$4.85K	﹤0.01%	4486
2025 Q2	$5.92K	Buy	524 +387	+282%	+$4.73K	﹤0.01%	4064
2025 Q1	$1.58K	Buy	137 +118	+621%	+$1.2K	﹤0.01%	4408
2024 Q4	$161	Hold	19	–	–	﹤0.01%	4670
2024 Q3	$220	Hold	19	–	–	﹤0.01%	4672
2024 Q2	$224	Buy	+19	New	+$222	﹤0.01%	4650
2024 Q1	–	Sell	-5	Closed	-$61	–	4758
2023 Q4	$61	Buy	+5	New	+$45	﹤0.01%	4545
2021 Q3	–	Sell	-59	Closed	-$1K	–	4356
2021 Q2	$1K	Buy	+59	New	+$1.54K	﹤0.01%	4123

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PNC Financial Services Group's KALV Position: Q1 2026 in Review

PNC Financial Services Group increased its KalVista Pharmaceuticals (KALV) stake by 2.1% in Q1 2026, buying an estimated $48 and bringing the position to 149 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #4459.

PNC Financial Services Group first reported a position in KALV in Q2 2021 and has held it in 10 quarters since. The position peaked at $5.92K in Q2 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

PNC Financial Services Group held 149 shares of KalVista Pharmaceuticals worth $3K as of Q1 2026.
PNC Financial Services Group bought 3 KalVista Pharmaceuticals shares in Q1 2026, an estimated $48.
KalVista Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4459 holding.
PNC Financial Services Group first reported a position in KalVista Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
PNC Financial Services Group's KalVista Pharmaceuticals position peaked at $5.92K in Q2 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.